Long-term patient experience with online MR-guided radiotherapy: adaptive versus non-adaptive workflow

Read full text
Authors: Fabian Weykamp, Charlotte Herder-Wagner, Sebastian Regnery, Jakob Liermann, Eva Meixner, Philipp Hoegen-Saßmannshausen, Laila König, Kristin Lang, Claudia Katharina Renkamp, Carolin Rippke, Sebastian Klüter, Jürgen Debus
+1 more Juliane Hörner‐Rieber
Cited by: 1
References: 46

Abstract

Purpose/objective Magnetic resonance–linear accelerator (MR-Linac) systems enable high-precision radiotherapy through real-time MR guidance and daily online adaptive treatment planning. While online adaptation offers substantial dosimetric advantages, it extends treatment session durations on an already resource-intensive platform. This study aimed to evaluate patient-reported outcome measures (PROMs) and long-term toxicity profiles associated with MR-guided radiotherapy, with a particular focus on the impact of online adaptive workflows. Materials and methods This subgroup analysis of an ongoing prospective observational study comprises patients treated with the MRIdian Linac at the Department of Radiation Oncology at Heidelberg University Hospital between January 2019 and May 2021. Online plan adaptation was implemented in February 2020. A custom-designed in-house questionnaire (PRO-Q) was employed to assess patient experience with MR-guided treatment. Toxicity was classified according to the Common Terminology Criteria for Adverse Events (CTCAE v. 5.0). Results A total of 231 patients were included, comprising 130 non-adaptive and 101 adaptive treatments across 286 target volumes. Baseline patient characteristics, prior systemic therapy, and median planning target volumes (36.4 mL vs . 35.3 mL) were comparable between groups. Adaptive treatment was associated with significantly prolonged session durations (median 71 minutes vs . 36 minutes; p

Fields of Study & Subjects

Advanced Radiotherapy Techniques Prostate Cancer Diagnosis and Treatment Radiation Therapy and Dosimetry

Publication details

Journal / source
Frontiers in Oncology
Publisher
Frontiers Media SA
Volume
16
Pages
1700649–1700649
Publication date
3 February 2026
Language
EN